KYMR
Kymera Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
KYMR Profile
Kymera Therapeutics, Inc.
A clinical-stage biopharmaceutical company that delivering novel small molecule protein degrader medicines used to degrade disease-causing proteins
Biological Technology
05/25/2017
08/21/2020
NASDAQ Stock Exchange
188
12-31
Common stock
200 Arsenal Yards Blvd., Suite 230, Watertown, Massachusetts 02472
--
Kymera Therapeutics, Inc., a limited liability company incorporated on May 25, 2017 under the laws of the State of Delaware. The company is a biopharmaceutical company dedicated to the discovery and development of novel small molecule therapies that selectively degrade disease-causing proteins by utilizing drugs.